文献速递瓣膜外科

心脏手术中含利多卡因心脏停搏液对人心的分子遗传学影响

Molecular Genetics of Lidocaine-Containing Cardioplegia in the Human Heart During Cardiac Surgery.
PubMed 文献 · Ann Thorac Surg · 2018-07-17

前瞻性纳入130例主动脉瓣置换术患者,比较含利多卡因(n=37)与不含利多卡因(n=93)高钾血心脏停搏液对左心室心肌基因表达的影响。对18,258个基因行差异表达分析,共1,298个基因差异表达;含利多卡因组上调基因经网络富集分析显示在缺血损伤中起保护作用,下调基因参与炎症性疾病、氧运输和中性粒细胞聚集。

要点

  • 含利多卡因心脏停搏液组与不含利多卡因组之间有1,298个基因差异表达。
  • 含利多卡因组上调基因经网络富集分析显示通过抑制凋亡、增加转铁蛋白内吞和增加细胞活力在缺血损伤中起保护作用。
  • 含利多卡因组下调基因被识别参与炎症性疾病、氧运输和中性粒细胞聚集。

核心结论

  • 在心脏停搏液中加入利多卡因在分子水平产生明显效应,涉及炎症减轻、细胞内钙结合减少、抗凋亡保护增强、通过转铁蛋白增加氧可及性以及细胞活力增加等基因的可测量差异。

研究设计与样本

  • 前瞻性纳入130例接受主动脉瓣置换手术的患者,含利多卡因组37例、不含利多卡因组93例,均接受高钾血心脏停搏液。
  • 在基线和平均74分钟冷心脏停搏后取左心室心尖活检,对18,258个基因行差异表达分析,并在模型中校正临床和人口学变量。
  • 使用g:Profiler和Cytoscape对保留基因行基因本体(GO)和网络富集分析。

主要发现

  • 含利多卡因组与不含利多卡因组心脏停搏处理之间有1,298个基因差异表达。
  • 与不含利多卡因组相比,含利多卡因组上调基因经网络富集分析显示通过抑制凋亡、增加转铁蛋白内吞和增加细胞活力在缺血损伤中起保护作用。
  • 含利多卡因组下调基因被识别参与炎症性疾病、氧运输和中性粒细胞聚集。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During cardiac surgery with cardiopulmonary bypass, delivery of cardioplegia solution to achieve electromechanical cardiac quiescence is obligatory. The addition of lidocaine to cardioplegia has advantages, although its consequences at a molecular level remain unclear. We performed whole-genome RNA sequencing of the human left ventricular (LV) myocardium to elucidate the differences between whole-blood (WB) cardioplegia with and without addition of lidocaine (LC) on gene expression. METHODS: We prospectively enrolled 130 patients undergoing aortic valve replacement surgery. Patients received high-potassium blood cardioplegia either with (n = 37) or without (n = 93) lidocaine. The LV apex was biopsied at baseline, and after an average of 74 minutes of cold cardioplegic arrest. We performed differential gene expression analysis for 18,258 genes between these 2 groups. Clinical and demographic variables were adjusted in the model. Gene ontology (GO) and network enrichment analysis of the retained genes were performed using g:Profiler and Cytoscape. RESULTS: A total of 1,298 genes were differentially expressed between cardioplegic treatments. Compared with the WB group, genes upregulated in the LC group were identified by network enrichment to play a protective role in ischemic injury by inhibiting apoptosis, increasing transferrin endocytosis, and increasing cell viability. Downregulated genes in the LC group were identified to play a role in inflammatory diseases, oxygen transport, and neutrophil aggregation. CONCLUSIONS: The addition of lidocaine to cardioplegia had pronounced effects on a molecular level with genes responsible for decreased inflammation, reduced intracellular calcium binding, enhanced antiapoptotic protection, augmented oxygen accessibility through transferrins, and increased cell viability showing measurable differences.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Heydarpour M, Ejiofor J, Gilfeather M, et al. Molecular Genetics of Lidocaine-Containing Cardioplegia in the Human Heart During Cardiac Surgery. Ann Thorac Surg. 2018. PMID: 30028983. doi:10.1016/j.athoracsur.2018.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。